Titan Medical Inc., a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System, a single-port robotic surgical system that comprises a surgeon-controlled patient cart, which includes a 3D vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during MIS procedures. The SPORT Surgical System enables surgeons to perform surgical procedures for gynecologic, urologic, colorectal, and general abdominal indications. Titan Medical Inc. is headquartered in Toronto, Canada.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone416-548-8522
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/8/2019 (Estimated)
OptionableNot Optionable
Titan Medical (NASDAQ:TMDI) Frequently Asked Questions
What is Titan Medical's stock symbol?
Titan Medical trades on the NASDAQ under the ticker symbol "TMDI."
How were Titan Medical's earnings last quarter?
Titan Medical Inc. (NASDAQ:TMDI) issued its quarterly earnings data on Wednesday, February, 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.24. View Titan Medical's Earnings History.
When is Titan Medical's next earnings date?
What price target have analysts set for TMDI?
2 brokerages have issued twelve-month price targets for Titan Medical's shares. Their forecasts range from $6.00 to $8.00. On average, they expect Titan Medical's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 159.8% from the stock's current price. View Analyst Price Targets for Titan Medical.
What is the consensus analysts' recommendation for Titan Medical?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Titan Medical in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Titan Medical.
What are Wall Street analysts saying about Titan Medical stock?
Here are some recent quotes from research analysts about Titan Medical stock:
- 1. According to Zacks Investment Research, "Titan Medical Inc. is focused on the design and development of a robotic surgical system for application in minimally invasive surgery. The Company's SPORT Surgical System includes a surgeon-controlled robotic platform which incorporates a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures through a single incision. The surgical system also includes a surgeon workstation which provides a surgeon with an advanced ergonomic interface to the robotic platform for controlling the instruments and viewing the inside of a patient's body in 3D during MIS procedures. Titan Medical Inc. is based in ON, Canada. " (4/11/2019)
- 2. Maxim Group analysts commented, "Market close, TMDI reported a wider-than-expected 4Q18 operating loss, but warrant exercises extend the cash runway. The company burned $17.8M of operating cash in the quarter, leaving it with $11.5M in cash and equivalents. a total of 619,606 warrants had been exercised for gross proceeds of $2.0M, and there are more in-the-money warrants. Titan’s SPORT Surgical system remains on track for a 510(k) submission by the end of 2019 and commercial launch in 2020. See Figure 1: TMDI Page 2." (2/14/2019)
- 3. Northland Securities analysts commented, "We just finished a call with Titan management, and highlight the key points discussed on our call. Overall, the company seems on track to file for CE mark by YE19 and begin its IDE study for the U.S. regulatory approval by Q4-19 also. We gleaned some additional details on these filings, which are highlighted below. Key Points U.S. 510k filing The U.S. IDE in anticipation of a 510k filing will begin in Q4-19. The IDE entails a 40-patient study in benign hysterectomy." (1/3/2019)
Has Titan Medical been receiving favorable news coverage?
Headlines about TMDI stock have trended somewhat positive on Friday, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Titan Medical earned a media sentiment score of 1.1 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the next several days.
Are investors shorting Titan Medical?
Titan Medical saw a drop in short interest during the month of March. As of March 29th, there was short interest totalling 283,027 shares, a drop of 43.7% from the March 15th total of 502,663 shares. Based on an average daily trading volume, of 252,458 shares, the short-interest ratio is currently 1.1 days. View Titan Medical's Current Options Chain.
Who are some of Titan Medical's key competitors?
Some companies that are related to Titan Medical include Nuvectra (NVTR), Apyx Medical (APYX), Liquidia Technologies (LQDA), Alphatec (ATEC), RenovaCare (RCAR), T2 Biosystems (TTOO), Sensus Healthcare (SRTS), Motus GI (MOTS), iCAD (ICAD), STRATA Skin Sciences (SSKN), Apollo Endosurgery (APEN), CAS Medical Systems (CASM), RA Medical Systems (RMED), Pro-Dex (PDEX) and Endologix (ELGX).
What other stocks do shareholders of Titan Medical own?
Who are Titan Medical's key executives?
Titan Medical's management team includes the folowing people:
- Mr. David J. McNally, Pres, CEO & Director (Age 57)
- Mr. Stephen D. Randall, CFO, Sec. & Director
- Dr. Perry A. Genova, Sr. VP of R&D
- Mr. Christopher Seibert, VP of Bus. Devel.
- Mr. Curtis R. Jensen, VP of Quality & Regulatory Affairs
How do I buy shares of Titan Medical?
Shares of TMDI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Titan Medical's stock price today?
One share of TMDI stock can currently be purchased for approximately $2.6942.
How big of a company is Titan Medical?
Titan Medical has a market capitalization of $58.40 million.
What is Titan Medical's official website?
How can I contact Titan Medical?
Titan Medical's mailing address is 170 UNIVERSITY AVENUE, TORONTO A6, M5H 3B3. The company can be reached via phone at 416-548-8522.
MarketBeat Community Rating for Titan Medical (NASDAQ TMDI)
MarketBeat's community ratings are surveys of what our community members think about Titan Medical and other stocks. Vote "Outperform" if you believe TMDI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TMDI will underperform the S&P 500 over the long term. You may vote once every thirty days.
